

!!NA_SEQUENCE 1.0
ID AAT93830 standard; DNA; 27 BP.
XX
AC AAT93830;
XX
DT 25-MAR-2003 (updated)
DI 24-FEB-1998 (first entry)
XX
DE Phosphodiester oligonucleotide 20 with cytotoxic activity.
XX
KW Phosphodiester; selective binding; cell viability; growth;
KW tumoural cell line; cytotoxic activity; tumour cell; lymphoma;
KW lymphoblastic tumour; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..27
FI /*tag= a
FI /note= "phosphodiester oligonucleotide"
XX
PN W09720924-A1.
XX
PD 12-JUN-1997.
XX
PF 04-DEC-1996; 96WO-EP05388.
XX
PR 04-DEC-1995; 95IT-MI02539.
XX
PA (SAIC-) SAICOM SRL.
XX
PI Quadrifoglio F, Scaggiante B;
XX
DR WPI: 1997-319771/29.
XX
PT New phospho:di:esteric oligo:nucleotide(s) - which exert a specific
PT and selective cytotoxic effect on tumour cells, for treating both
PT solid and liquid tumours
XX
PS Example 4: Page 11: 38pp: English.
XX
CC Novel phosphodiesteric oligonucleotides AAT93830-33 are based on the
CC generic formula, in the 3'-5' or 5'-3' direction:
CC (GaTa'a'a''-(GbTb'b''-(GcTc'c''-(Gdtd'd''-(GeTe'e''-(GfTf'f''-
CC (G-gTg'g''-N', where:
CC N and N' = T or G, equal or different from each other;
CC x = 0-8, equal or different from each other;
CC a, b, c, d, e, f, and g = 0-10, equal or different from each other;
CC a', b', c', d', e', f', and g' = 0-30, equal or different from each
CC other;
CC a'', b'', c'', d'', e'', f'', and g'' = 1-16, equal or different from
CC each other;
CC The oligonucleotides (see also AAT93811-27) are believed to selectively
CC bind and sequester some proteins which are essential to the viability
CC and growth of tumoural cell lines. They have specific and selective
CC cytotoxic activity against tumour cells, and can be used for treating
CC tumours of the liquid type, in particular of lymphoblastic origin, and of
CC the solid type, in particular lymphomas. These oligonucleotides were
CC created to determine the relevance of the repeating unit (Gtn) for
CC cytotoxic activity. The results for oligonucleotides AAT93830-33 show
CC that oligonucleotides having (CT), (AT), and (GC) repeating units cannot
CC significantly alter the cellular growth, while the oligonucleotide
CC containing the (GA) repeating unit is only poorly toxic at high
CC concentrations.
CC (Updated on 25-MAR-2003 to correct PR field.)
XX
SQ Sequence 27 BP; 0 A; 7 C; 0 G; 20 T; 0 other;
AAT93830 Length: 27 October 6, 2003 10:11 Type: N Check: 86 ..
1 TCTTCTCTTC TTCTTCTTCTT TCTTCTC

```
!!NA_SEQUENCE 1.0
ID AAT93833 standard; DNA; 27 BP.
XX
AC AAT93833;
XX
DI 25-MAR-2003 (updated)
DT 24-FEB-1998 (first entry)
XX
DE Phosphodiester oligonucleotide 23 with cytotoxic activity.
XX
KW Phosphodiester; selective binding; cell viability; growth;
KW tumoural cell line; cytotoxic activity; tumour cell; lymphoma;
KW lymphoblastic tumour; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..27
FT /*tag= a
FT /note= "phosphodiester oligonucleotide"
XX
PN WO9720924-A1.
XX
PD 12-JUN-1997.
XX
PF 04-DEC-1996; 96WO-EP05388.
XX
PR 04-DEC-1995; 95IT-M102539.
XX
PA (SAIC-) SAICOM SRL.
XX
PI Quadrifoglio F, Scaggiante B;
XX
WPI; 1997-319771/29.
XX
New phosphodiesteric oligonucleotide(s) - which exert a specific
and selective cytotoxic effect on tumour cells, for treating both
solid and liquid tumours
XX
Example 4; Page 11; 38pp; English.
XX
Novel phosphodiesteric oligonucleotides AAT93830-33 are based on the
generic formula, in the 3'-5' or 5'-3' direction:
(GaTa')a''-(GbTb')b''-(GcTc')c''-(GdTd')d''-(GeTe')e''-(GfTf')f''-
(GgTg')g''-N', where:
N and N' = T or G, equal or different from each other;
x = 0-8, equal or different from each other;
a, b, c, d, e, f, and g = 0-10, equal or different from each other;
a', b', c', d', e', f', and g' = 0-30, equal or different from each
other;
a'', b'', c'', d'', e'', f'', and g'' = 1-16, equal or different from
each other;
The oligonucleotides (see also AAT93811-27) are believed to selectively
bind and sequester some proteins which are essential to the viability
and growth of tumoural cell lines. They have specific and selective
cytotoxic activity against tumour cells, and can be used for treating
tumours of the liquid type, in particular of lymphoblastic origin, and of
the solid type, in particular lymphomas. These oligonucleotides were
created to determine the relevance of the repeating unit (GTn) for
cytotoxic activity. The results for oligonucleotides AAT93830-33 show
that oligonucleotides having (CT), (AT), and (GC) repeating units cannot
significantly alter the cellular growth, while the oligonucleotide
containing the (GA) repeating unit is only poorly toxic at high
concentrations.
CC (Updated on 25-MAR-2003 to correct PR field.)
XX
SQ Sequence 27 BP; 20 A; 0 C; 7 G; 0 U; 0 other;
AAT93833 Length: 27 October 6, 2003 10:11 Type: N Check: 5158 ..
```

```

!!NA_SEQUENCE 1.0
ID ABS54657 standard; DNA: 26 BP.
XX
XX AC ABS54657;
XX
XX DT 03-DEC-2002 (first entry)
XX
XX DE Human p53 protein chromosomal binding region oligonucleotide Hooq1.
XX
XX DE Human; ss; p53; chromosomal binding region; cancer; carcinoma; sarcoma;
KW breast cancer; adrenal cortex cancer; colon cancer; bladder cancer;
KW prostate cancer; lung cancer; leukaemic cancer.
XX
XX OS Homo sapiens.
XX
XX PN US2002103153-A1.
XX
XX PD 01-AUG-2002.
XX
XX PF 22-AUG-2001: 2001US-0935247.
XX
XX PR 01-MAY-1992: 92US-0879618.
XX
XX PR 15-AUG-1994: 94US-0291011.
XX
XX PR 10-MAR-1999: 99US-0266065.
XX
XX PR 06-APR-1992: 92US-0863661.
XX
XX (RERR/) RE R.
XX
XX PA (COOK/) COOK J.
XX
XX PI Re R, Cook J;
XX
XX DR WPI: 2002-674027/72.
XX
XX PT Composition for treating cancer comprises an oligonucleotide that binds
XX a chromosomal binding site for p53.
XX
XX PS Claim 5: Page 3: 13pp; English.
XX
XX CC The invention relates to composition comprising an oligonucleotide that
XX can bind a chromosomal binding site for p53 protein, and a
XX pharmaceutically acceptable carrier. The composition is useful for
XX inhibiting mammalian (e.g. human, ape, monkey, cow, mouse, rat, hamster,
XX rabbit, cat, sheep or bull, dog, horse) cell growth and replication,
XX especially cancer (e.g. carcinoma, sarcoma, breast cancer, adrenal cortex
XX cancer, colon cancer, bladder cancer, prostate cancer, lung cancer or
XX leukaemic cancer). The present sequence is human p53 protein chromosomal
XX binding region oligonucleotide Hooq1 which binds at position 70-95
XX of the sequence appearing as ABS54650.
XX
XX SQ Sequence 26 BP; 0 A; 7 C; 0 G; 19 T; 0 other;
ABS54657 Length: 26 October 6, 2003 10:11 Type: N Check: 7597 ..
1 TTCTTCTT TCITTCITC TTTC

```